A robust RNAi cardiometabolic pipeline is advancing, with plozasiran showing sustained triglyceride reductions and a strong safety profile, zodasiran demonstrating durable LDL-C lowering in HoFH, and ARO-DIMER-PA targeting dual lipid pathways. Key data readouts and regulatory filings are expected in late 2026 and 2027.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.